Results 221 to 230 of about 2,444,013 (293)
Recurrence Risk in Lateralized Floor of Mouth Carcinoma: Depth of Invasion Versus Midline Distance
ABSTRACT Background Contralateral nodal recurrence in lateralized floor‐of‐mouth squamous cell carcinoma (OSCC) remains difficult to predict, and objective preoperative parameters to guide contralateral neck management in tumors without midline crossing are lacking.
Jannik Ketschau +10 more
wiley +1 more source
Robust flat-magnetoresistivity in D0<sub>3</sub>-Fe<sub>3</sub>Ga driven by chiral anomaly. [PDF]
Wang R +13 more
europepmc +1 more source
ABSTRACT Background Immunotherapy is increasingly used for head and neck cutaneous squamous cell carcinoma (cSCC) with perineural spread (PNS), though outcomes remain poorly defined. Methods A systematic review was conducted according to PRISMA and MOOSE guidelines.
Jai Paris +4 more
wiley +1 more source
Clinical Applicability of the WHO Reporting System for Axillary Lymph Node Fine-Needle Aspiration in Invasive Breast Carcinoma. [PDF]
Canepa M, Chang A, Graff SL, Wang Y.
europepmc +1 more source
ABSTRACT Background In T1–T2 oropharyngeal squamous cell carcinoma (OPSCC), factors associated with patient‐reported quality of life after transoral robotic surgery (TORS) are poorly defined. Methods Retrospective cohort of 59 patients with T1–T2 OPSCC treated with TORS.
Paolo Tesauro +5 more
wiley +1 more source
End-to-End PET/CT Interpretation and Quantification with an LLM-Orchestrated AI Agent: A Real-World Pilot Study. [PDF]
Choi H, Bae S, Na KJ.
europepmc +1 more source
Aerogel Fiber: A One‐Dimensional Programmable Porous Matter for Next Thermal Management Materials
Aerogel fibers are redefined as one‐dimensional programmable porous matter, where thermal transport is governed by multiscale pathway engineering. By reconstructing and decoupling transport pathways from molecular to textile scales, these systems integrate insulation, radiative cooling, and adaptive thermal regulation.
Lizhi Ren +6 more
wiley +1 more source
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt +7 more
wiley +1 more source
ABSTRACT Local recurrence after primary breast cancer treatment remains a complex clinical scenario in patients previously treated with breast‐conserving therapy and radiotherapy. For decades, salvage mastectomy was considered the standard treatment for ipsilateral breast tumor recurrence, largely because of concerns about local control after repeat ...
Cezara Cheptea +4 more
wiley +1 more source

